Literature DB >> 8542909

Technetium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma.

S Kosuda1, H Yokoyama, M Katayama, T Yokokawa, S Kusano, O Yamamoto.   

Abstract

A 79-year-old male with follicular thyroid carcinoma metastasizing to the lung, bone and lymph nodes was subjected to whole-body scintigraphy using technetium-99m tetrofosmin and 99mTc-sestamibi. Both agents delineated the metastatic lesions and the two image qualities were comparable. We believe that 99mTc-tetrofosmin and 99mTc-sestamibi images may be helpful in localizing metastatic foci and substitute for thallium-201 in the follow-up of patients with differentiated thyroid carcinoma.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8542909     DOI： 10.1007/bf00800609

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN： 0340-6997


  23 in total

1.  Role of thallium-201 total-body scintigraphy in follow-up of thyroid carcinoma.

Authors:  C A Hoefnagel; C C Delprat; H R Marcuse; J J de Vijlder
Journal:  J Nucl Med       Date:  1986-12       Impact factor: 10.057

2.  Thallium-201 SPECT increases detectability of thyroid cancer metastases.

Authors:  N D Charkes; R A Vitti; K Brooks
Journal:  J Nucl Med       Date:  1990-02       Impact factor: 10.057

3.  201ti scintigraphy in postoperative detection of thyroid cancer: a comparative study with 131i.

Authors:  N Tonami; K Hisada
Journal:  Radiology       Date:  1980-08       Impact factor: 11.105

4.  Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies.

Authors:  M J O'Doherty; A G Kettle; P Wells; R E Collins; A J Coakley
Journal:  J Nucl Med       Date:  1992-03       Impact factor: 10.057

5.  Technetium-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m-MDP.

Authors:  B Caner; M Kitapçl; M Unlü; G Erbengi; T Calikoğlu; T Göğüş; C Bekdik
Journal:  J Nucl Med       Date:  1992-03       Impact factor: 10.057

6.  Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma.

Authors:  A J Brendel; M Guyot; R Jeandot; G Lefort; G Manciet
Journal:  J Nucl Med       Date:  1988-09       Impact factor: 10.057

7.  Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study)

Authors:  R Taillefer; Y Boucher; C Potvin; R Lambert
Journal:  J Nucl Med       Date:  1992-10       Impact factor: 10.057

8.  Human biodistribution, dosimetry and clinical use of technetium(III)-99m-Q12.

Authors:  C Rossetti; G Vanoli; G Paganelli; M Kwiatkowski; F Zito; F Colombo; C Bonino; A Carpinelli; R Casati; K Deutsch
Journal:  J Nucl Med       Date:  1994-10       Impact factor: 10.057

9.  Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: a within-subject comparison.

Authors:  L A O'Tuama; S T Treves; J N Larar; A B Packard; A J Kwan; P D Barnes; R M Scott; P M Black; J R Madsen; L C Goumnerova
Journal:  J Nucl Med       Date:  1993-07       Impact factor: 10.057

10.  Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi.

Authors:  V V Rao; M L Chiu; J F Kronauge; D Piwnica-Worms
Journal:  J Nucl Med       Date:  1994-03       Impact factor: 10.057
View more
  1 in total

1.  Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management.

Authors:  Di Wu; Dorina Ylli; Cristiane J Gomes Lima; Wen Lee; Kenneth D Burman; Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2018-05-24       Impact factor: 3.633
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.